Anemia is a leading symptom of CRF' and is present in over 9096 of the
dialyzed patients. Introduction of recombinant human erythropoietirt
(rHuEPo) into routine therapy of uraemic anemia has dramatically reduced
or even eliminated the need of blood transfusion and improved the
quality of life .
All CKD patients with renal anemia undergoing treatment with rHuEPO
should be given supplementary iron to maintain or reach the Hb targets.
Regardless of dialysis status Iron deficiency is the most important
cause of a suboptimal response to rHuEpo therapy ,determing the proper
dose is a chnilrnge topic.
* This work has been carried out to evaluate efficacy of Reticvlolyte
Hemoglobin Content (CHr) in management of anemia in CRY under dialysis.
Our study included 50 patients with ESRD on hernodialysis divided
into 2 groups, (A) include 25 patient with E.S.R.D where Anemia management
depend on Transfenin Saturation (MAT%) and serum ferittin and
group (B) with ESRD where anemia management depend on CHr and serg
umferittin
In our study we found that:
* There was no significant difference between group A and B as regard
CRP(11.8±5.5 and 9.7+3.9 p>0.05 ) and also no dyference in
Hb96 at the start and end of study of both groups(8.9+I .9 - 7.6±I.7
p>0,05 andl 0.6+2.9- 10. 1+2.8 respectively)
* There was significance difference between the two group as regarding
doses of IX iron (mg) and doses of rHuEPo (units). |
